TINZAPARIN SODIUM
All strengths: Limited Use — Reason for Use code 186, 187, 188, 189, 323 required; same patient cost rules
Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 186, 187, 188, 189, 323 required
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (B01A, B01AB) — coverage varies; not interchangeable
- Enoxaparin (Noromby): general benefit
- Dalteparin (Fragmin): limited Use 186, 187, 188, 189
- Nadroparin (Fraxiparine): limited Use 186, 187, 188, 189
- Apixaban (Eliquis): general benefit
- Dabigatran etexilate (Pradaxa): general benefit, Not a benefit
- Edoxaban (Lixiana): general benefit
5 more in the class list below
Innohep · DIN 02358158 · 3500IU/0.35mL · injection, pre-filled syringe
Limited Use — Reason for Use code 186, 187, 188, 189, 323 requiredMarketed · checked 2026-09-02
Write on scriptLU code 186, 187, 188, 189, 323 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189, 323
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 323
For the acute treatment of pulmonary embolism, maximum of three weeks.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 29, record 8, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: 2,500 IU, 3,500 IU, 4,500 IU, 8,000 IU, 10,000 IU, 12,000
IU, 14,000 IU, 16,000 IU, 18,000 IU, 20,000 IU Injection
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.,
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin. 10
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery.
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
470
Oral Hypoglycemic Agents
Note: Prescribers do not need to make an EAP request for patients currently receiving
pioglitazone or rosiglitazone through ODB. Physicians will be required to make an
application for coverage for any patient new to ODB that is being started on either of these
drugs or any ODB recipient who is new to using these drugs.
Requests for ongoing treatment with pioglitazone or rosiglitazone for patients who were
previously covered by other means may be considered according to renewal criteria.
Funding under the EAP for pioglitazone or rosiglitazone will not be provided in the
following clinical settings:
• Patients with type 1 diabetes
• Monotherapy, even if patient is intolerant or has contraindications to both metformin
and sulfonlyureas
• Combination use with either nitrates or insulin
• Patients with any stage of heart failure (NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (post-menopausal women with previously
confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of ischemic cardiovascular event
(myocardial infarction, unstable angina)
• Patients with active bladder cancer, a history of bladder cancer or uninvestigated
macroscopic haematuria
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 470, record 309, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)No interchangeable product listed in the Ontario extract
Innohep · DIN 02358158
Manufacturer: Leo Pharma Inc.; listing date 2011-08-04
Health Canada: Marketed since 2011-09-09 · brand INNOHEP · ATC B01AB10 TINZAPARIN · form Solution · route Subcutaneous · ingredients TINZAPARIN SODIUM 10000 UNIT/ML · company Leo pharma inc · schedule Prescription
Innohep: Formulary list price $10.2157/unit (unit not stated in source; not the patient's cost)
Ministry pays: $10.2157 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84321 · Verify on the e-Formulary ↗ (DIN 02358158)
Source record
DIN 02358158: Innohep
Raw flags: sec12=Y, sec3=Y
Item: 201200044; group id 262; item number 0516; lccId 00048; manufacturer id LEO
Source form: Inj Pref Syr; strength: 3500IU/0.35mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $10.2157; ministry $10.2157
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02358158
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84321
Shortage status: resolved shortage (ended 2020-03-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02358158
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Innohep · DIN 02358166 · 4500IU/0.45mL · injection, pre-filled syringe
Limited Use — Reason for Use code 186, 187, 188, 189, 323 requiredMarketed · checked 2026-09-02
Write on scriptLU code 186, 187, 188, 189, 323 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189, 323
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 323
For the acute treatment of pulmonary embolism, maximum of three weeks.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 29, record 8, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: 2,500 IU, 3,500 IU, 4,500 IU, 8,000 IU, 10,000 IU, 12,000
IU, 14,000 IU, 16,000 IU, 18,000 IU, 20,000 IU Injection
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.,
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin. 10
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery.
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
470
Oral Hypoglycemic Agents
Note: Prescribers do not need to make an EAP request for patients currently receiving
pioglitazone or rosiglitazone through ODB. Physicians will be required to make an
application for coverage for any patient new to ODB that is being started on either of these
drugs or any ODB recipient who is new to using these drugs.
Requests for ongoing treatment with pioglitazone or rosiglitazone for patients who were
previously covered by other means may be considered according to renewal criteria.
Funding under the EAP for pioglitazone or rosiglitazone will not be provided in the
following clinical settings:
• Patients with type 1 diabetes
• Monotherapy, even if patient is intolerant or has contraindications to both metformin
and sulfonlyureas
• Combination use with either nitrates or insulin
• Patients with any stage of heart failure (NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (post-menopausal women with previously
confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of ischemic cardiovascular event
(myocardial infarction, unstable angina)
• Patients with active bladder cancer, a history of bladder cancer or uninvestigated
macroscopic haematuria
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 470, record 309, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)No interchangeable product listed in the Ontario extract
Innohep · DIN 02358166
Manufacturer: Leo Pharma Inc.; listing date 2011-08-04
Health Canada: Marketed since 2011-12-10 · brand INNOHEP · ATC B01AB10 TINZAPARIN · form Solution · route Subcutaneous · ingredients TINZAPARIN SODIUM 10000 UNIT/ML · company Leo pharma inc · schedule Prescription
Innohep: Formulary list price $13.1374/unit (unit not stated in source; not the patient's cost)
Ministry pays: $13.1374 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84322 · Verify on the e-Formulary ↗ (DIN 02358166)
Source record
DIN 02358166: Innohep
Raw flags: sec12=Y, sec3=Y
Item: 201200045; group id 262; item number 0517; lccId 00048; manufacturer id LEO
Source form: Inj Pref Syr; strength: 4500IU/0.45mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $13.1374; ministry $13.1374
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02358166
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84322
Shortage status: resolved shortage (ended 2020-03-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02358166
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Innohep · DIN 02429462 · 8000IU/0.4mL · injection, pre-filled syringe
Limited Use — Reason for Use code 186, 187, 188, 189, 323 requiredMarketed · checked 2026-09-02
Write on scriptLU code 186, 187, 188, 189, 323 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189, 323
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 323
For the acute treatment of pulmonary embolism, maximum of three weeks.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 29, record 8, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: 2,500 IU, 3,500 IU, 4,500 IU, 8,000 IU, 10,000 IU, 12,000
IU, 14,000 IU, 16,000 IU, 18,000 IU, 20,000 IU Injection
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.,
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin. 10
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery.
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
470
Oral Hypoglycemic Agents
Note: Prescribers do not need to make an EAP request for patients currently receiving
pioglitazone or rosiglitazone through ODB. Physicians will be required to make an
application for coverage for any patient new to ODB that is being started on either of these
drugs or any ODB recipient who is new to using these drugs.
Requests for ongoing treatment with pioglitazone or rosiglitazone for patients who were
previously covered by other means may be considered according to renewal criteria.
Funding under the EAP for pioglitazone or rosiglitazone will not be provided in the
following clinical settings:
• Patients with type 1 diabetes
• Monotherapy, even if patient is intolerant or has contraindications to both metformin
and sulfonlyureas
• Combination use with either nitrates or insulin
• Patients with any stage of heart failure (NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (post-menopausal women with previously
confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of ischemic cardiovascular event
(myocardial infarction, unstable angina)
• Patients with active bladder cancer, a history of bladder cancer or uninvestigated
macroscopic haematuria
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 470, record 309, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)No interchangeable product listed in the Ontario extract
Innohep · DIN 02429462
Manufacturer: Leo Pharma Inc.; listing date 2015-08-26
Health Canada: Marketed since 2014-09-30 · brand INNOHEP · ATC B01AB10 TINZAPARIN · form Solution · route Subcutaneous · ingredients TINZAPARIN SODIUM 8000 UNIT/0.4ML · company Leo pharma inc · schedule Prescription
Innohep: Formulary list price $22.7208/unit (unit not stated in source; not the patient's cost)
Ministry pays: $22.7208 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91392 · Verify on the e-Formulary ↗ (DIN 02429462)
Source record
DIN 02429462: Innohep
Raw flags: sec12=Y, sec3=Y
Item: 201200095; group id 262; item number 0513; lccId 00048; manufacturer id LEO
Source form: Inj Pref Syr; strength: 8000IU/0.4mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $22.7208; ministry $22.7208
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429462
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91392
Shortage status: resolved shortage (ended 2019-11-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429462
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Innohep · DIN 02231478 · 10000IU/0.5mL · injection, pre-filled syringe
Limited Use — Reason for Use code 186, 187, 188, 189, 323 requiredMarketed · checked 2026-09-02
Write on scriptLU code 186, 187, 188, 189, 323 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189, 323
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 323
For the acute treatment of pulmonary embolism, maximum of three weeks.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 29, record 8, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: 2,500 IU, 3,500 IU, 4,500 IU, 8,000 IU, 10,000 IU, 12,000
IU, 14,000 IU, 16,000 IU, 18,000 IU, 20,000 IU Injection
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.,
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin. 10
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery.
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
470
Oral Hypoglycemic Agents
Note: Prescribers do not need to make an EAP request for patients currently receiving
pioglitazone or rosiglitazone through ODB. Physicians will be required to make an
application for coverage for any patient new to ODB that is being started on either of these
drugs or any ODB recipient who is new to using these drugs.
Requests for ongoing treatment with pioglitazone or rosiglitazone for patients who were
previously covered by other means may be considered according to renewal criteria.
Funding under the EAP for pioglitazone or rosiglitazone will not be provided in the
following clinical settings:
• Patients with type 1 diabetes
• Monotherapy, even if patient is intolerant or has contraindications to both metformin
and sulfonlyureas
• Combination use with either nitrates or insulin
• Patients with any stage of heart failure (NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (post-menopausal women with previously
confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of ischemic cardiovascular event
(myocardial infarction, unstable angina)
• Patients with active bladder cancer, a history of bladder cancer or uninvestigated
macroscopic haematuria
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 470, record 309, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)No interchangeable product listed in the Ontario extract
Innohep · DIN 02231478
Manufacturer: Leo Pharma Inc.; listing date 1998-12-31
Health Canada: Marketed since 2011-09-08 · brand INNOHEP · ATC B01AB10 TINZAPARIN · form Solution · route Subcutaneous · ingredients TINZAPARIN SODIUM 20000 UNIT/ML · company Leo pharma inc · schedule Prescription
Innohep: Formulary list price $29.7939/unit (unit not stated in source; not the patient's cost)
Ministry pays: $29.7939 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50802 · Verify on the e-Formulary ↗ (DIN 02231478)
Source record
DIN 02231478: Innohep
Raw flags: sec12=Y, sec3=Y
Item: 201200046; group id 262; item number 0518; lccId 00048; manufacturer id LEO
Source form: Inj Pref Syr; strength: 10000IU/0.5mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $29.7939; ministry $29.7939
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231478
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50802
Shortage status: resolved shortage (ended 2019-12-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02231478
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Innohep · DIN 02167840 · 10000IU/mL · injection-2mL Pk
Limited Use — Reason for Use code 186, 187, 188, 189, 323 requiredMarketed · checked 2026-09-02
Write on scriptLU code 186, 187, 188, 189, 323 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189, 323
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 323
For the acute treatment of pulmonary embolism, maximum of three weeks.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 29, record 8, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: 2,500 IU, 3,500 IU, 4,500 IU, 8,000 IU, 10,000 IU, 12,000
IU, 14,000 IU, 16,000 IU, 18,000 IU, 20,000 IU Injection
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.,
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin. 10
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery.
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
470
Oral Hypoglycemic Agents
Note: Prescribers do not need to make an EAP request for patients currently receiving
pioglitazone or rosiglitazone through ODB. Physicians will be required to make an
application for coverage for any patient new to ODB that is being started on either of these
drugs or any ODB recipient who is new to using these drugs.
Requests for ongoing treatment with pioglitazone or rosiglitazone for patients who were
previously covered by other means may be considered according to renewal criteria.
Funding under the EAP for pioglitazone or rosiglitazone will not be provided in the
following clinical settings:
• Patients with type 1 diabetes
• Monotherapy, even if patient is intolerant or has contraindications to both metformin
and sulfonlyureas
• Combination use with either nitrates or insulin
• Patients with any stage of heart failure (NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (post-menopausal women with previously
confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of ischemic cardiovascular event
(myocardial infarction, unstable angina)
• Patients with active bladder cancer, a history of bladder cancer or uninvestigated
macroscopic haematuria
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 470, record 309, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)No interchangeable product listed in the Ontario extract
Innohep · DIN 02167840
Manufacturer: Leo Pharma Inc.; listing date 1997-04-10
Health Canada: Marketed since 1995-12-31 · brand INNOHEP · ATC B01AB10 TINZAPARIN · form Solution · route Subcutaneous · ingredients TINZAPARIN SODIUM 10000 UNIT/ML · company Leo pharma inc · schedule Prescription
Innohep: Formulary list price $55.1469/unit (unit not stated in source; not the patient's cost)
Ministry pays: $55.1469 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19202 · Verify on the e-Formulary ↗ (DIN 02167840)
Source record
DIN 02167840: Innohep
Raw flags: sec12=Y, sec3=Y
Item: 201200039; group id 262; item number 0521; lccId 00048; manufacturer id LEO
Source form: Inj-2mL Pk; strength: 10000IU/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $55.1469; ministry $55.1469
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02167840
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19202
Shortage status: shortage reported ended 2026-08-06 (report last updated 2026-08-06); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02167840
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Innohep · DIN 02429470 · 12000IU/0.6mL · injection, pre-filled syringe
Limited Use — Reason for Use code 186, 187, 188, 189, 323 requiredMarketed · checked 2026-09-02
Write on scriptLU code 186, 187, 188, 189, 323 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189, 323
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 323
For the acute treatment of pulmonary embolism, maximum of three weeks.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 29, record 8, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: 2,500 IU, 3,500 IU, 4,500 IU, 8,000 IU, 10,000 IU, 12,000
IU, 14,000 IU, 16,000 IU, 18,000 IU, 20,000 IU Injection
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.,
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin. 10
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery.
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
470
Oral Hypoglycemic Agents
Note: Prescribers do not need to make an EAP request for patients currently receiving
pioglitazone or rosiglitazone through ODB. Physicians will be required to make an
application for coverage for any patient new to ODB that is being started on either of these
drugs or any ODB recipient who is new to using these drugs.
Requests for ongoing treatment with pioglitazone or rosiglitazone for patients who were
previously covered by other means may be considered according to renewal criteria.
Funding under the EAP for pioglitazone or rosiglitazone will not be provided in the
following clinical settings:
• Patients with type 1 diabetes
• Monotherapy, even if patient is intolerant or has contraindications to both metformin
and sulfonlyureas
• Combination use with either nitrates or insulin
• Patients with any stage of heart failure (NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (post-menopausal women with previously
confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of ischemic cardiovascular event
(myocardial infarction, unstable angina)
• Patients with active bladder cancer, a history of bladder cancer or uninvestigated
macroscopic haematuria
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 470, record 309, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)No interchangeable product listed in the Ontario extract
Innohep · DIN 02429470
Manufacturer: Leo Pharma Inc.; listing date 2015-08-26
Health Canada: Marketed since 2014-09-30 · brand INNOHEP · ATC B01AB10 TINZAPARIN · form Solution · route Subcutaneous · ingredients TINZAPARIN SODIUM 12000 UNIT/0.6ML · company Leo pharma inc · schedule Prescription
Innohep: Formulary list price $35.7866/unit (unit not stated in source; not the patient's cost)
Ministry pays: $35.7866 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91393 · Verify on the e-Formulary ↗ (DIN 02429470)
Source record
DIN 02429470: Innohep
Raw flags: sec12=Y, sec3=Y
Item: 201200096; group id 262; item number 0514; lccId 00048; manufacturer id LEO
Source form: Inj Pref Syr; strength: 12000IU/0.6mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $35.7866; ministry $35.7866
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429470
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91393
Shortage status: resolved shortage (ended 2020-04-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429470
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Innohep · DIN 02358174 · 14000IU/0.7mL · injection, pre-filled syringe
Limited Use — Reason for Use code 186, 187, 188, 189, 323 requiredMarketed · checked 2026-09-02
Write on scriptLU code 186, 187, 188, 189, 323 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189, 323
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 323
For the acute treatment of pulmonary embolism, maximum of three weeks.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 29, record 8, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: 2,500 IU, 3,500 IU, 4,500 IU, 8,000 IU, 10,000 IU, 12,000
IU, 14,000 IU, 16,000 IU, 18,000 IU, 20,000 IU Injection
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.,
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin. 10
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery.
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
470
Oral Hypoglycemic Agents
Note: Prescribers do not need to make an EAP request for patients currently receiving
pioglitazone or rosiglitazone through ODB. Physicians will be required to make an
application for coverage for any patient new to ODB that is being started on either of these
drugs or any ODB recipient who is new to using these drugs.
Requests for ongoing treatment with pioglitazone or rosiglitazone for patients who were
previously covered by other means may be considered according to renewal criteria.
Funding under the EAP for pioglitazone or rosiglitazone will not be provided in the
following clinical settings:
• Patients with type 1 diabetes
• Monotherapy, even if patient is intolerant or has contraindications to both metformin
and sulfonlyureas
• Combination use with either nitrates or insulin
• Patients with any stage of heart failure (NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (post-menopausal women with previously
confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of ischemic cardiovascular event
(myocardial infarction, unstable angina)
• Patients with active bladder cancer, a history of bladder cancer or uninvestigated
macroscopic haematuria
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 470, record 309, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)No interchangeable product listed in the Ontario extract
Innohep · DIN 02358174
Manufacturer: Leo Pharma Inc.; listing date 2011-08-04
Health Canada: Marketed since 2011-09-16 · brand INNOHEP · ATC B01AB10 TINZAPARIN · form Solution · route Subcutaneous · ingredients TINZAPARIN SODIUM 20000 UNIT/ML · company Leo pharma inc · schedule Prescription
Innohep: Formulary list price $41.7497/unit (unit not stated in source; not the patient's cost)
Ministry pays: $41.7497 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84323 · Verify on the e-Formulary ↗ (DIN 02358174)
Source record
DIN 02358174: Innohep
Raw flags: sec12=Y, sec3=Y
Item: 201200047; group id 262; item number 0519; lccId 00048; manufacturer id LEO
Source form: Inj Pref Syr; strength: 14000IU/0.7mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $41.7497; ministry $41.7497
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02358174
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84323
Shortage status: resolved shortage (ended 2019-10-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02358174
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Innohep · DIN 02429489 · 16000IU/0.8mL · injection, pre-filled syringe
Limited Use — Reason for Use code 186, 187, 188, 189, 323 requiredMarketed · checked 2026-09-02
Write on scriptLU code 186, 187, 188, 189, 323 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189, 323
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 323
For the acute treatment of pulmonary embolism, maximum of three weeks.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 29, record 8, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: 2,500 IU, 3,500 IU, 4,500 IU, 8,000 IU, 10,000 IU, 12,000
IU, 14,000 IU, 16,000 IU, 18,000 IU, 20,000 IU Injection
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.,
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin. 10
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery.
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
470
Oral Hypoglycemic Agents
Note: Prescribers do not need to make an EAP request for patients currently receiving
pioglitazone or rosiglitazone through ODB. Physicians will be required to make an
application for coverage for any patient new to ODB that is being started on either of these
drugs or any ODB recipient who is new to using these drugs.
Requests for ongoing treatment with pioglitazone or rosiglitazone for patients who were
previously covered by other means may be considered according to renewal criteria.
Funding under the EAP for pioglitazone or rosiglitazone will not be provided in the
following clinical settings:
• Patients with type 1 diabetes
• Monotherapy, even if patient is intolerant or has contraindications to both metformin
and sulfonlyureas
• Combination use with either nitrates or insulin
• Patients with any stage of heart failure (NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (post-menopausal women with previously
confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of ischemic cardiovascular event
(myocardial infarction, unstable angina)
• Patients with active bladder cancer, a history of bladder cancer or uninvestigated
macroscopic haematuria
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 470, record 309, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)No interchangeable product listed in the Ontario extract
Innohep · DIN 02429489
Manufacturer: Leo Pharma Inc.; listing date 2015-08-26
Health Canada: Marketed since 2014-09-30 · brand INNOHEP · ATC B01AB10 TINZAPARIN · form Solution · route Subcutaneous · ingredients TINZAPARIN SODIUM 16000 UNIT/0.8ML · company Leo pharma inc · schedule Prescription
Innohep: Formulary list price $47.7158/unit (unit not stated in source; not the patient's cost)
Ministry pays: $47.7158 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91394 · Verify on the e-Formulary ↗ (DIN 02429489)
Source record
DIN 02429489: Innohep
Raw flags: sec12=Y, sec3=Y
Item: 201200097; group id 262; item number 0515; lccId 00048; manufacturer id LEO
Source form: Inj Pref Syr; strength: 16000IU/0.8mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $47.7158; ministry $47.7158
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429489
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91394
Shortage status: resolved shortage (ended 2020-04-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02429489
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Innohep · DIN 02358182 · 18000IU/0.9mL · injection, pre-filled syringe
Limited Use — Reason for Use code 186, 187, 188, 189, 323 requiredMarketed · checked 2026-09-02
Write on scriptLU code 186, 187, 188, 189, 323 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189, 323
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 323
For the acute treatment of pulmonary embolism, maximum of three weeks.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 29, record 8, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: 2,500 IU, 3,500 IU, 4,500 IU, 8,000 IU, 10,000 IU, 12,000
IU, 14,000 IU, 16,000 IU, 18,000 IU, 20,000 IU Injection
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.,
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin. 10
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery.
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
470
Oral Hypoglycemic Agents
Note: Prescribers do not need to make an EAP request for patients currently receiving
pioglitazone or rosiglitazone through ODB. Physicians will be required to make an
application for coverage for any patient new to ODB that is being started on either of these
drugs or any ODB recipient who is new to using these drugs.
Requests for ongoing treatment with pioglitazone or rosiglitazone for patients who were
previously covered by other means may be considered according to renewal criteria.
Funding under the EAP for pioglitazone or rosiglitazone will not be provided in the
following clinical settings:
• Patients with type 1 diabetes
• Monotherapy, even if patient is intolerant or has contraindications to both metformin
and sulfonlyureas
• Combination use with either nitrates or insulin
• Patients with any stage of heart failure (NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (post-menopausal women with previously
confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of ischemic cardiovascular event
(myocardial infarction, unstable angina)
• Patients with active bladder cancer, a history of bladder cancer or uninvestigated
macroscopic haematuria
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 470, record 309, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)No interchangeable product listed in the Ontario extract
Innohep · DIN 02358182
Manufacturer: Leo Pharma Inc.; listing date 2011-08-04
Health Canada: Marketed since 2011-09-13 · brand INNOHEP · ATC B01AB10 TINZAPARIN · form Solution · route Subcutaneous · ingredients TINZAPARIN SODIUM 20000 UNIT/ML · company Leo pharma inc · schedule Prescription
Innohep: Formulary list price $53.6727/unit (unit not stated in source; not the patient's cost)
Ministry pays: $53.6727 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84324 · Verify on the e-Formulary ↗ (DIN 02358182)
Source record
DIN 02358182: Innohep
Raw flags: sec12=Y, sec3=Y
Item: 201200048; group id 262; item number 0520; lccId 00048; manufacturer id LEO
Source form: Inj Pref Syr; strength: 18000IU/0.9mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $53.6727; ministry $53.6727
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02358182
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84324
Shortage status: resolved shortage (ended 2019-12-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02358182
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Innohep · DIN 02229515 · 20000IU/mL · injection-2mL Pk
Limited Use — Reason for Use code 186, 187, 188, 189, 323 requiredMarketed · checked 2026-09-02
Write on scriptLU code 186, 187, 188, 189, 323 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189, 323
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 323
For the acute treatment of pulmonary embolism, maximum of three weeks.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 29, record 8, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: 2,500 IU, 3,500 IU, 4,500 IU, 8,000 IU, 10,000 IU, 12,000
IU, 14,000 IU, 16,000 IU, 18,000 IU, 20,000 IU Injection
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.,
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin. 10
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery.
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
470
Oral Hypoglycemic Agents
Note: Prescribers do not need to make an EAP request for patients currently receiving
pioglitazone or rosiglitazone through ODB. Physicians will be required to make an
application for coverage for any patient new to ODB that is being started on either of these
drugs or any ODB recipient who is new to using these drugs.
Requests for ongoing treatment with pioglitazone or rosiglitazone for patients who were
previously covered by other means may be considered according to renewal criteria.
Funding under the EAP for pioglitazone or rosiglitazone will not be provided in the
following clinical settings:
• Patients with type 1 diabetes
• Monotherapy, even if patient is intolerant or has contraindications to both metformin
and sulfonlyureas
• Combination use with either nitrates or insulin
• Patients with any stage of heart failure (NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (post-menopausal women with previously
confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of ischemic cardiovascular event
(myocardial infarction, unstable angina)
• Patients with active bladder cancer, a history of bladder cancer or uninvestigated
macroscopic haematuria
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 470, record 309, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)No interchangeable product listed in the Ontario extract
Innohep · DIN 02229515
Manufacturer: Leo Pharma Inc.; listing date 1998-12-31
Health Canada: Marketed since 1997-02-28 · brand INNOHEP · ATC B01AB10 TINZAPARIN · form Solution · route Subcutaneous · ingredients TINZAPARIN SODIUM 20000 UNIT/ML · company Leo pharma inc · schedule Prescription
Innohep: Formulary list price $117.6245/unit (unit not stated in source; not the patient's cost)
Ministry pays: $117.6245 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47420 · Verify on the e-Formulary ↗ (DIN 02229515)
Source record
DIN 02229515: Innohep
Raw flags: sec12=Y, sec3=Y
Item: 201200042; group id 262; item number 0522; lccId 00048; manufacturer id LEO
Source form: Inj-2mL Pk; strength: 20000IU/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $117.6245; ministry $117.6245
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02229515
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=47420
Shortage status: anticipated shortage (last updated 2026-08-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02229515
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Innohep · PIN 09857367 · 2500IU/0.25mL · injection, pre-filled syringe
Limited Use — Reason for Use code 186, 187, 188, 189, 323 requiredOntario PIN; no Health Canada record under this code
Write on scriptLU code 186, 187, 188, 189, 323 (patient must meet the criteria below)
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check Health Canada brand searchPrivate plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE
Ontario Limited Use criteria — code 186, 187, 188, 189, 323
Reason for Use code 186
For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 187
For DVT in pregnant or lactating females;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 188
For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 189
For DVT in patients who have failed treatment with warfarin.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 323
For the acute treatment of pulmonary embolism, maximum of three weeks.
Coverage limit:
LU Authorization Period: 1 year
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products
For peri-operative bridging for patients who require long-term warfarin therapy and must
temporarily discontinue it before and after surgery, and who are at moderate- to high-risk
for an embolic event while off warfarin.
Standard Approval Duration: As requested up to a maximum of 10 days before the date
of surgery plus up to 7 days after surgery.
For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and
cannot use warfarin.
Standard Approval Duration: As requested up to a maximum of 30 days starting on the
day of surgery.
For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or risk
factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 29, record 8, corpus 2025-01-01; name match only, not an eligibility decision
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive):
Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange
Tinzaparin
Brand(s): Innohep
DOSAGE FORM/ STRENGTH: 2,500 IU, 3,500 IU, 4,500 IU, 8,000 IU, 10,000 IU, 12,000
IU, 14,000 IU, 16,000 IU, 18,000 IU, 20,000 IU Injection
1. For peri-operative bridging for patients who require long-term warfarin therapy and
must temporarily discontinue it before and after surgery, and who are at moderate- to
high-risk for an embolic event while off warfarin.,
Standard Approval Duration: As requested up to a maximum of 10 days before the
date of surgery plus up to 7 days after the date of hospital discharge
2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and
cannot use warfarin. 10
Standard Approval Duration: As requested up to a maximum of 30 days starting on
the day of surgery.
3. For the post-operative prophylaxis of venous thromboembolism following
abdominal or pelvic surgery for cancer in patients who do not have a history of or
risk factors for heparin-induced thrombocytopenia.
Standard Approval Duration: Maximum of 30 days.
470
Oral Hypoglycemic Agents
Note: Prescribers do not need to make an EAP request for patients currently receiving
pioglitazone or rosiglitazone through ODB. Physicians will be required to make an
application for coverage for any patient new to ODB that is being started on either of these
drugs or any ODB recipient who is new to using these drugs.
Requests for ongoing treatment with pioglitazone or rosiglitazone for patients who were
previously covered by other means may be considered according to renewal criteria.
Funding under the EAP for pioglitazone or rosiglitazone will not be provided in the
following clinical settings:
• Patients with type 1 diabetes
• Monotherapy, even if patient is intolerant or has contraindications to both metformin
and sulfonlyureas
• Combination use with either nitrates or insulin
• Patients with any stage of heart failure (NYHA Class I, II, III, IV)
• Patients at high risk for bone fracture (post-menopausal women with previously
confirmed osteoporosis or osteopenia)
• Patients with recent history (in the past 3 months) of ischemic cardiovascular event
(myocardial infarction, unstable angina)
• Patients with active bladder cancer, a history of bladder cancer or uninvestigated
macroscopic haematuria
EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 470, record 309, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times
The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used.
Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE.
EAP Weekly Progress Report
Date: September 15, 2026
Processing categories and examples | Target | Current |
Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day |
Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days |
Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days |
Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
(ontario.ca, Updated September 15, 2026 ↗)
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
(ontario.ca, Updated September 15, 2026 ↗)No interchangeable product listed in the Ontario extract
Innohep · DIN 09857367
Manufacturer: Leo Pharma Inc.; listing date 2010-07-20
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Innohep: Formulary list price $7.3042/unit (unit not stated in source; not the patient's cost)
Ministry pays: $7.3042 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857367)
Source record
DIN 09857367: Innohep
Raw flags: sec12=Y, sec3=Y
Item: 201200081; group id 262; item number 0512; lccId 00048; manufacturer id LEO
Source form: Inj Pref Syr; strength: 2500IU/0.25mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $7.3042; ministry $7.3042
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857367
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09857367
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (20:12 Coagulants and Anti-Coagulants) and how they are covered
Matched class: 20:12 Coagulants and Anti-Coagulants
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: APIXABAN, ENOXAPARIN, RIVAROXABAN
Some products covered without a code (check the product listing): DABIGATRAN ETEXILATE, EDOXABAN, WARFARIN
20:12 Coagulants and Anti-Coagulants
· 37 products · General benefit · strengths: 20mg/0.2mL, 30mg/0.3mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 120mg/0.8mL, 100mg/mL, 150mg/mL, 300mg/3mL · Inj Sol-0.2mL Pref Syr (Preservative-Free), Inj Sol-0.3mL Pref Syr (Preservative-Free), Inj Sol-0.4mL Pref Syr (Preservative-Free), Inj Sol-0.6mL Pref Syr (Preservative-Free), Inj Sol-0.8mL Pref Syr (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free), Inj Sol-3mL Vial Pk (With Preservative)
· 10 products ·
Limited Use, codes 186, 187, 188, 189 · strengths: 3500IU/0.28mL, 7500IU/0.3mL, 2500IU/0.2mL, 5000IU/0.2mL, 10000IU/0.4mL, 12500IU/0.5mL, 15000IU/0.6mL, 18000IU/0.72mL, 16500IU/0.66mL, 25000IU/mL · Inj Pref Syr, Inj Pref Syr-0.66mL Pk, Multidose 3.8mL Pk
· 7 products ·
Limited Use, codes 186, 187, 188, 189 · strengths: 9500IU/mL, 19000IU/mL · Pref Syr-0.3mL Pk, Pref Syr-0.4mL Pk, Pref Syr-0.6mL Pk, Pref Syr-0.8mL Pk, Pref Syr-1.0mL Pk
· 38 products · General benefit · strengths: 2.5mg, 5mg · Tab
· 6 products · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (4) · strengths: 75mg, 110mg, 150mg · Cap
· 48 products · General benefit · strengths: 2.5mg, 10mg, 15mg, 20mg · Tab
· 23 products · Listed, not a benefit (8), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (1) · strengths: 1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 10mg · Tab
· 4 products ·
Limited Use, codes 378 (2), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 2.5mg/0.5mL, 7.5mg/0.6mL · Inj Sol-Pref Syr 0.5mL Pk (Preservative Free), Inj Sol-Pref Syr 0.6mL Pk (Preservative Free)
· 10 products · Off-Formulary Interchangeable, not an ODB benefit (5),
Limited Use, codes 441 (5) · strengths: 60mg, 90mg · Tab
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.75mg/mL, 2mg/mL · 100mL Vial Pk, 10mL Vial Pk
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12
20:12:04 Direct Factor Xa Inhibitors
· 11 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (8) · strengths: 15mg, 30mg, 60mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12:04
20:12:16 Hemostatics
· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12:16